Liqiang Hu Selected Research

Liqiang Hu Research Topics

Disease

15	Neoplasms (Cancer) 03/2024 - 08/2011
5	Pancreatitis 04/2023 - 01/2017
2	Colorectal Neoplasms (Colorectal Cancer) 09/2023 - 01/2019
2	Insulin Resistance 07/2022 - 01/2022
2	Diabetes Complications 07/2022 - 01/2022
2	Body Weight (Weight, Body) 07/2022 - 01/2022
2	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 05/2013
2	COVID-19 01/2021 - 01/2021
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 11/2018
1	Sepsis (Septicemia) 01/2024
1	Renal Insufficiency (Renal Failure) 01/2024
1	Periodontal Diseases (Periodontal Disease) 11/2023
1	Breast Neoplasms (Breast Cancer) 10/2023
1	Carcinogenesis 10/2023
1	Inflammation (Inflammations) 01/2023
1	Colonic Neoplasms (Colon Cancer) 01/2023
1	Lipid Metabolism Disorders (Metabolism Disorders, Lipid) 01/2022
1	Communicable Diseases (Infectious Diseases) 01/2021
1	Infections 01/2021
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2021
1	Immune System Diseases (Immune Disorders) 08/2020
1	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 08/2020
1	Carcinoma (Carcinomatosis) 08/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020
1	Arteriosclerosis Obliterans 01/2020
1	Liver Neoplasms (Liver Cancer) 10/2019
1	Lung Neoplasms (Lung Cancer) 01/2019
1	Diabetes Mellitus 10/2018
1	Chondrosarcoma 01/2018
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2017

Drug/Important Bio-Agent (IBA)

3	Therapeutic UsesIBA 01/2022 - 09/2015
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2024 - 01/2018
2	AntioxidantsIBA 01/2024 - 10/2018
2	Messenger RNA (mRNA)IBA 10/2023 - 09/2023
2	Hypoglycemic Agents (Hypoglycemics)IBA 07/2022 - 01/2022
2	Blood Glucose (Blood Sugar)IBA 07/2022 - 01/2022
2	Glucose (Dextrose)FDA LinkGeneric 07/2022 - 01/2022
2	Long Noncoding RNAIBA 01/2022 - 01/2021
2	VaccinesIBA 01/2021 - 01/2021
2	Peptides (Polypeptides)IBA 01/2020 - 01/2019
2	Gemcitabine FDA Link 11/2018 - 09/2015
2	OSI 027IBA 01/2017 - 09/2015
1	Cysteine (L-Cysteine)FDA Link 03/2024
1	CalciumIBA 03/2024
1	Proteins (Proteins, Gene)FDA Link 03/2024
1	A-Form DNA (A-DNA)IBA 01/2024
1	HydrogelsIBA 11/2023
1	DNA (Deoxyribonucleic Acid)IBA 11/2023
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 10/2023
1	AnnexinsIBA 09/2023
1	CeruletideIBA 04/2023
1	sini tangIBA 01/2023
1	CytokinesIBA 01/2023
1	LipidsIBA 07/2022
1	Histidine (L-Histidine)FDA Link 07/2022
1	Uric Acid (Urate)IBA 07/2022
1	AcidsIBA 07/2022
1	Amino Acids FDA Link 07/2022
1	chaiqin chengqiIBA 05/2022
1	KynurenineIBA 01/2022
1	Valine (L-Valine)FDA Link 01/2022
1	Triglycerides (Triacylglycerol)IBA 01/2022
1	Branched-Chain Amino AcidsIBA 01/2022
1	Sorafenib (BAY 43-9006)FDA Link 01/2022
1	Leucine (L-Leucine)FDA Link 01/2022
1	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 01/2022
1	PhosphatidylserinesIBA 01/2022
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2022
1	Inositol (Myoinositol)IBA 01/2022
1	PhosphatidylglycerolsIBA 01/2022
1	Isoleucine (L-Isoleucine)FDA Link 01/2022
1	taurolithocholic acid 3-sulfate (TLC-S)IBA 05/2021
1	Glycoproteins (Glycoprotein)IBA 01/2021
1	Imatinib Mesylate (Gleevec)FDA Link 01/2021
1	Proteolysis Targeting ChimeraIBA 01/2021
1	Antiviral Agents (Antivirals)IBA 01/2021
1	Butyrates (Butyrate)IBA 01/2021
1	NucleotidesIBA 01/2021
1	GlycopeptidesIBA 08/2020
1	Immunoglobulins (Immunoglobulin)IBA 08/2020
1	Biomarkers (Surrogate Marker)IBA 08/2020
1	Cisplatin (Platino)FDA LinkGeneric 01/2020
1	MicroRNAs (MicroRNA)IBA 01/2020
1	HSP27 Heat-Shock ProteinsIBA 01/2020
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2019
1	Neuropilin-1IBA 01/2019
1	UbiquitinIBA 01/2019
1	IntegrinsIBA 01/2019
1	N-end cysteine peptide tumor-homing peptideIBA 01/2019
1	degrasynIBA 11/2018
1	Ubiquitin-Specific ProteasesIBA 11/2018
1	PhytochemicalsIBA 10/2018
1	FlavonoidsIBA 10/2018
1	Free RadicalsIBA 01/2018
1	PQQ Cofactor (Pyrroloquinoline Quinone)IBA 01/2018
1	Oxygen (Dioxygen)IBA 01/2018
1	Taurocholic Acid (Sodium Taurocholate)IBA 01/2017
1	PhenolsIBA 01/2017

Therapy/Procedure

6	Therapeutics 05/2022 - 10/2019
1	Drug Therapy (Chemotherapy) 10/2019